Literature DB >> 22541309

Predictors of cardiometabolic risk among adults with cerebral palsy.

Mark D Peterson1, Heidi J Haapala, Edward A Hurvitz.   

Abstract

OBJECTIVE: To examine the independent association between various anthropometric indicators and standard clinical markers of cardiometabolic health risk among adults with cerebral palsy (CP).
DESIGN: Cross-sectional study.
SETTING: Clinical center for CP treatment and rehabilitation. PARTICIPANTS: Adults with CP (N=43) with a mean age ± SD of 37.3±13.2 years, and Gross Motor Function Classification System (GMFCS) levels of I-V.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Adults with CP were assessed for body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), waist-to-height ratio (WtHR), and serum lipid profiles. Data were analyzed with multiple regression analysis and general linear models, and are reported as means ± SDs.
RESULTS: Mean BMI was 29.1±7.8kg/m(2). BMI was not associated with any measures of cardiometabolic risk. Using GMFCS categories (2 groups: GMFCS levels I-III and IV-V), BMI was significantly lower among GMFCS levels IV-V (24.2±6.2kg/m(2)) versus GMFCS levels I-III (30.1±7.6kg/m(2)). WC and WtHR were not correlated with any cardiometabolic outcomes. Conversely, measures of WHR were independently associated with various indices of risk, including total cholesterol to high-density lipoprotein (HDL) cholesterol ratio (r=.45; P<.05), HDL cholesterol (r=-.51; P<.01), and triglycerides (r=.40; P<.05), suggesting that greater WHR was indicative of elevated risk.
CONCLUSIONS: It is likely that WHR represents a stronger predictor of risk, because this measure was robustly and independently associated with 3 primary clinical markers of cardiometabolic health in adults with CP.
Copyright © 2012 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541309     DOI: 10.1016/j.apmr.2011.12.024

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  7 in total

1.  Multimorbidity in Middle-Aged Adults with Cerebral Palsy.

Authors:  Nicole Cremer; Edward A Hurvitz; Mark D Peterson
Journal:  Am J Med       Date:  2017-01-05       Impact factor: 4.965

2.  Greater Adipose Tissue Distribution and Diminished Spinal Musculoskeletal Density in Adults With Cerebral Palsy.

Authors:  Mark D Peterson; Peng Zhang; Heidi J Haapala; Stewart C Wang; Edward A Hurvitz
Journal:  Arch Phys Med Rehabil       Date:  2015-07-02       Impact factor: 3.966

Review 3.  Exercise and physical activity recommendations for people with cerebral palsy.

Authors:  Olaf Verschuren; Mark D Peterson; Astrid C J Balemans; Edward A Hurvitz
Journal:  Dev Med Child Neurol       Date:  2016-02-07       Impact factor: 5.449

4.  Associations of sedentary behaviour, physical activity, blood pressure and anthropometric measures with cardiorespiratory fitness in children with cerebral palsy.

Authors:  Jennifer M Ryan; Owen Hensey; Brenda McLoughlin; Alan Lyons; John Gormley
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

5.  Noncommunicable disease among adults with cerebral palsy: A matched cohort study.

Authors:  Jennifer M Ryan; Mark D Peterson; Anthony Matthews; Nicola Ryan; Kimberley J Smith; Neil E O'Connell; Silvia Liverani; Nana Anokye; Christina Victor; Elizabeth Allen
Journal:  Neurology       Date:  2019-08-28       Impact factor: 9.910

6.  Eating and drinking ability and nutritional status in adults with cerebral palsy.

Authors:  Anita McAllister; Eva Sjöstrand; Elisabet Rodby-Bousquet
Journal:  Dev Med Child Neurol       Date:  2022-02-28       Impact factor: 4.864

7.  Abdominal obesity is an independent predictor of serum 25-hydroxyvitamin D deficiency in adults with cerebral palsy.

Authors:  Mark D Peterson; Heidi J Haapala; Ashish Chaddha; Edward A Hurvitz
Journal:  Nutr Metab (Lond)       Date:  2014-05-19       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.